Gene · 8405
Papers2,215
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,215
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets. | Cell Death Discov | 2023 | 38135679 | PubTator, text mining | PubMed |
| Phase separations in oncogenesis, tumor progressions and metastasis: a glance from hallmarks of cancer. | J Hematol Oncol | 2023 | 38110976 | PubTator, text mining | PubMed |
| The involvement of E3 ubiquitin ligases in the development and progression of colorectal cancer. | Cell Death Discov | 2023 | 38104139 | PubTator, text mining | PubMed |
| Correction: CUL3/SPOP complex prevents immune escape and enhances chemotherapy sensitivity of ovarian cancer cells through degradation of PD-L1 protein. | J Immunother Cancer | 2023 | 38101867 | PubTator, text mining | PubMed |
| The deubiquitinating enzyme USP44 suppresses hepatocellular carcinoma progression by inhibiting Hedgehog signaling and PDL1 expression. | Cell Death Dis | 2023 | 38097536 | PubTator, text mining | PubMed |
| Case report: Squamous cell carcinoma of the prostate-a clinicopathological and genomic sequencing-based investigation. | Pathol Oncol Res | 2023 | 38089646 | PubTator, text mining | PubMed |
| Integrated Genomic Analysis of Primary Prostate Tumor Foci and Corresponding Lymph Node Metastases Identifies Mutations and Pathways Associated with Metastasis. | Cancers (Basel) | 2023 | 38067373 | PubTator, text mining | PubMed |
| Role of Chromatin and Epigenetic Dysregulation in Prostate Cancer: From Development to Progression and Therapeutic Response. | Cancers (Basel) | 2023 | 38067340 | PubTator, text mining | PubMed |
| Molecular Alterations in Intraductal Carcinoma of the Prostate. | Cancers (Basel) | 2023 | 38067216 | PubTator, text mining | PubMed |
| Erratum: SPOP targets oncogenic protein ZBTB3 for destruction to suppress endometrial cancer. | Am J Cancer Res | 2023 | 38058828 | PubTator, text mining | PubMed |
| Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities. | Res Rep Urol | 2023 | 38050587 | PubTator, text mining | PubMed |
| CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion. | J Clin Invest | 2023 | 38038129 | PubTator, text mining | PubMed |
| Dynamic RBM47 ISGylation confers broad immunoprotection against lung injury and tumorigenesis via TSC22D3 downregulation. | Cell Death Discov | 2023 | 38036512 | PubTator, text mining | PubMed |
| Roles of estrogen receptor α in endometrial carcinoma (Review). | Oncol Lett | 2023 | 38020303 | PubTator, text mining | PubMed |
| SPOP inhibits HBV transcription and replication by ubiquitination and degradation of HNF1α. | J Med Virol | 2023 | 38018242 | Swiss-Prot, curated | PubMed |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell Rep Med | 2023 | 38016482 | PubTator, text mining | PubMed |
| CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma. | J Immunother Cancer | 2023 | 38007240 | PubTator, text mining | PubMed |
| PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas. | Int J Mol Sci | 2023 | 38003535 | PubTator, text mining | PubMed |
| CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy. | Int J Mol Sci | 2023 | 38003514 | PubTator, text mining | PubMed |
| Intraductal Carcinoma of the Prostate: To Grade or Not to Grade. | Cancers (Basel) | 2023 | 38001579 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8405/papers?page=12